Insights From Technical Analysis

4DMedical (ASX: 4DX): Pricing the Future of Lung Imaging

Sep 21, 2026

Proactive Equities Team

4DMedical is scaling its lung-imaging software portfolio, led by CT:VQ, across hospitals and imaging networks. FY26 scan volumes rose 77% to 344,075, while cash reached A$278m; however, the company remains loss-making as it pursues commercial adoption and revenue growth.

Read more

AdAlta (ASX: 1AD) $120M Deal: Proof of Platform, Not Profit

Sep 21, 2026

Proactive Equities Team

While AdAlta (ASX: 1AD) is not the recipient of the $120 million deal, this agreement could do wonders for its IRO technology platform by validating it and making future product development through the platform easier and faster.

Read more

Mount Ridley Mines (ASX: MRD): Selectro Process Impresses as Shares Approach Resistance

Sep 21, 2026

Proactive Equities Team

Mount Ridley Mines (ASX: MRD) achieved a 91.8% scandium recovery breakthrough with its Selectro™ process, using half the reagent dose, at its largest scandium resource. Shares trade in an uptrend, though technicals suggest limited room for an entry at current levels.

Read more

Why KTEK Aerosystems (ASX:KTK) 's $200k Defence Deal Is a Huge Opportunity

Sep 21, 2026

Proactive Equities Team

KTEK Aerosystems (ASX: KTK) secured its first order from a major Israeli defence prime, a modest US$200,000 milestone within a US$994,100 work package. The real opportunity is a potential US$5 million pipeline, contingent on clearing upcoming engineering reviews and further customer orders.

Read more

Mithril Silver and Gold (ASX: MTH): Copalquin Resource Growth Meets a Key Chart Test

Sep 18, 2026

Proactive Equities Team

Mithril Silver and Gold (ASX: MTH) is advancing its Copalquin district in Mexico, where Target 1 now hosts over 600,000 ounces of gold equivalent. Drilling continues across newer targets, while shares remain in a downtrend, needing a strong break above resistance to signal a reversal.

Read more

Bubs Australia (ASX: BUB): BUB's Rally Could Be Just Getting Started

Sep 18, 2026

Proactive Equities Team

Bubs Australia enters FY27 with permanent FDA approval, wider US distribution and strong American revenue growth. The company is expanding retail channels and rebuilding other markets, but higher freight costs, tariffs, negative EBITDA, and working-capital demands keep profitability and execution in focus.

Read more